Drug Trial Radar · NCT06246071
A Study of TYK-00540 in Adult Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Jan 2, 2024
Primary completion
Dec 5, 2026
Study completion Dec 5, 2026
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of TYK-00540, with dose-escalation stage and dose-expansion stage.
Conditions
- Locally Advanced or Metastatic Solid Tumors
Interventions
TYK-00540Drug
TYK-00540 PO, BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)Time frame: Within 31 days of the first dose
- Recommended dose for combination-agent escalation and single-agent expansion (RDE)Time frame: 1 year
- Adverse events (AEs)Time frame: From Baseline up to 28 days after the end of the treatment
- Objective response rate (ORR)Time frame: At least 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.